|
Cyclo Therapeutics Inc (NASDAQ: CYTH) |
|
Cyclo Therapeutics Inc
CYTH's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Cyclo Therapeutics Inc 's sales fell
by -52.82 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1274
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -1.86 %
Cyclo Therapeutics Inc net loss increased from $-5 millions, to $-9 millions in III. Quarter 2024,
• More on CYTH's Growth
|
|
Cyclo Therapeutics Inc realized a net loss in trailing twelve months.
Cyclo Therapeutics Inc realized cash reduction of $ -0.03 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 30.69.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.68.
• More on CYTH's Valuation
|
|
|
|
|
Cyclo Therapeutics Inc realized net loss in trailing twelve months.
Cyclo Therapeutics Inc realized cash outflow of $ -0.03per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 30.69.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.68.
• More on CYTH's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com